Nantkwest (NK) Shares Up -1.5%
Nantkwest Inc (NASDAQ:NK) shot up 1.5% during trading on Wednesday . The stock traded as high as $4.16 and last traded at $3.98. 113,087 shares changed hands during mid-day trading, a decline of 60% from the average session volume of 279,540 shares. The stock had previously closed at $4.04.
Several research firms recently commented on NK. Zacks Investment Research cut Nantkwest from a “buy” rating to a “hold” rating in a report on Wednesday, January 10th. BidaskClub lowered Nantkwest from a “sell” rating to a “strong sell” rating in a research report on Friday, January 19th. Finally, Raymond James Financial reiterated a “hold” rating on shares of Nantkwest in a research report on Monday, December 11th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $5.25.
The firm has a market cap of $293.98, a PE ratio of -3.20 and a beta of 3.16. The company has a quick ratio of 5.47, a current ratio of 5.47 and a debt-to-equity ratio of 0.01.
Nantkwest Company Profile
NantKwest, Inc is a clinical-stage immunotherapy company. The Company is focused on harnessing the power of the innate immune system by using the natural killer cell to treat cancer, infectious diseases and inflammatory diseases. Its immuno-oncology NK platform has multiple modes to induce cell death against the tumor or infected cell by direct killing by binding to stress ligands expressed by the diseased cell with the release of toxic granules directly into the tumor cell; antibody mediated killing by binding to antibodies administered in combination and enhancing the cancer killing effect of the administered antibody, enabling targeted cell killing through antibody dependent cellular cytotoxicity (ADCC), and target activated killing by binding to known or newly discovered tumor-specific antigens expressed on the surface of tumor cells and inducing cell death by the release of toxic granules directly into the tumor cell and by the release of cytokines and chemokines.
Receive News & Ratings for Nantkwest Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nantkwest and related companies with MarketBeat.com's FREE daily email newsletter.